ResearcherMassachusetts General HospitalActive in the last 2 years
Fidel López‐Verdugo
Matched on ORCID iD 0000-0001-8231-8095; OpenAlex author ID A5082998918. Sources: OpenAlex.
Their work
- Papers
- 3 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 13
2023: 2 papers · 2024: 1 paper
Papers 3
- Tumor Size Reduction and Serum Carbohydrate Antigen 19-9 Kinetics After Neoadjuvant FOLFIRINOX in Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.surg.2023.09.041↗
- Underlying Bias in the Treatment of Pancreatic Cancer: Minorities Treated at the Same Facilities are Less Likely to Receive Neoadjuvant Therapy. Co-author DOI 10.1097/sla.0000000000005354↗
- Tolerability, Attrition Rates, and Survival Outcomes of Neoadjuvant FOLFIRINOX for Nonmetastatic Pancreatic Adenocarcinoma: Intent-to-Treat Analysis. First author DOI 10.1097/xcs.0000000000000499↗
Closest collaborators
The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Zhi Ven Fong · 3 shared papers, 2023–2024 · strength 0.54
- Paper Tumor Size Reduction and Serum Carbohydrate Antigen 19-9 Kinetics After Neoadjuvant FOLFIRINOX in Patients With Pancrea… DOI 10.1016/j.surg.2023.09.041↗
- Paper Underlying Bias in the Treatment of Pancreatic Cancer: Minorities Treated at the Same Facilities are Less Likely to Rec… DOI 10.1097/sla.0000000000005354↗
- Paper Tolerability, Attrition Rates, and Survival Outcomes of Neoadjuvant FOLFIRINOX for Nonmetastatic Pancreatic Adenocarcin… DOI 10.1097/xcs.0000000000000499↗
- Carlos F. Fernandez-del Castillo · 3 shared papers, 2023–2024 · strength 0.54
- Paper Tumor Size Reduction and Serum Carbohydrate Antigen 19-9 Kinetics After Neoadjuvant FOLFIRINOX in Patients With Pancrea… DOI 10.1016/j.surg.2023.09.041↗
- Paper Underlying Bias in the Treatment of Pancreatic Cancer: Minorities Treated at the Same Facilities are Less Likely to Rec… DOI 10.1097/sla.0000000000005354↗
- Paper Tolerability, Attrition Rates, and Survival Outcomes of Neoadjuvant FOLFIRINOX for Nonmetastatic Pancreatic Adenocarcin… DOI 10.1097/xcs.0000000000000499↗
- Motaz Qadan · 3 shared papers, 2023–2024 · strength 0.54
- Paper Tumor Size Reduction and Serum Carbohydrate Antigen 19-9 Kinetics After Neoadjuvant FOLFIRINOX in Patients With Pancrea… DOI 10.1016/j.surg.2023.09.041↗
- Paper Underlying Bias in the Treatment of Pancreatic Cancer: Minorities Treated at the Same Facilities are Less Likely to Rec… DOI 10.1097/sla.0000000000005354↗
- Paper Tolerability, Attrition Rates, and Survival Outcomes of Neoadjuvant FOLFIRINOX for Nonmetastatic Pancreatic Adenocarcin… DOI 10.1097/xcs.0000000000000499↗
- Cristina Rosa Ferrone · 3 shared papers, 2023–2024 · strength 0.54
- Paper Tumor Size Reduction and Serum Carbohydrate Antigen 19-9 Kinetics After Neoadjuvant FOLFIRINOX in Patients With Pancrea… DOI 10.1016/j.surg.2023.09.041↗
- Paper Underlying Bias in the Treatment of Pancreatic Cancer: Minorities Treated at the Same Facilities are Less Likely to Rec… DOI 10.1097/sla.0000000000005354↗
- Paper Tolerability, Attrition Rates, and Survival Outcomes of Neoadjuvant FOLFIRINOX for Nonmetastatic Pancreatic Adenocarcin… DOI 10.1097/xcs.0000000000000499↗
- Keith D. Lillemoe · 3 shared papers, 2023–2024 · strength 0.54
- Paper Tumor Size Reduction and Serum Carbohydrate Antigen 19-9 Kinetics After Neoadjuvant FOLFIRINOX in Patients With Pancrea… DOI 10.1016/j.surg.2023.09.041↗
- Paper Underlying Bias in the Treatment of Pancreatic Cancer: Minorities Treated at the Same Facilities are Less Likely to Rec… DOI 10.1097/sla.0000000000005354↗
- Paper Tolerability, Attrition Rates, and Survival Outcomes of Neoadjuvant FOLFIRINOX for Nonmetastatic Pancreatic Adenocarcin… DOI 10.1097/xcs.0000000000000499↗
- Theodore Sunki Hong · 2 shared papers, 2023 · strength 0.33
- Paper Underlying Bias in the Treatment of Pancreatic Cancer: Minorities Treated at the Same Facilities are Less Likely to Rec… DOI 10.1097/sla.0000000000005354↗
- Paper Tolerability, Attrition Rates, and Survival Outcomes of Neoadjuvant FOLFIRINOX for Nonmetastatic Pancreatic Adenocarcin… DOI 10.1097/xcs.0000000000000499↗
- Lawrence Scott Blaszkowsky · 2 shared papers, 2023 · strength 0.33
- Paper Underlying Bias in the Treatment of Pancreatic Cancer: Minorities Treated at the Same Facilities are Less Likely to Rec… DOI 10.1097/sla.0000000000005354↗
- Paper Tolerability, Attrition Rates, and Survival Outcomes of Neoadjuvant FOLFIRINOX for Nonmetastatic Pancreatic Adenocarcin… DOI 10.1097/xcs.0000000000000499↗
- Aparna R. Parikh · 2 shared papers, 2023 · strength 0.33
- Paper Underlying Bias in the Treatment of Pancreatic Cancer: Minorities Treated at the Same Facilities are Less Likely to Rec… DOI 10.1097/sla.0000000000005354↗
- Paper Tolerability, Attrition Rates, and Survival Outcomes of Neoadjuvant FOLFIRINOX for Nonmetastatic Pancreatic Adenocarcin… DOI 10.1097/xcs.0000000000000499↗
- Jennifer Yon-Li Wo · 2 shared papers, 2023 · strength 0.33
- Paper Underlying Bias in the Treatment of Pancreatic Cancer: Minorities Treated at the Same Facilities are Less Likely to Rec… DOI 10.1097/sla.0000000000005354↗
- Paper Tolerability, Attrition Rates, and Survival Outcomes of Neoadjuvant FOLFIRINOX for Nonmetastatic Pancreatic Adenocarcin… DOI 10.1097/xcs.0000000000000499↗
- Guoliang Qiao · 1 shared paper, 2024 · strength 0.21
- Maximiliano Servín-Rojas · 1 shared paper, 2024 · strength 0.21
- David P. Ryan · 1 shared paper, 2023 · strength 0.16
- Colin D. Weekes · 1 shared paper, 2023 · strength 0.16
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.